Summary
3.90 0.16(4.28%)06/26/2024
Rani Therapeutics Holdings Inc (RANI)
Rani Therapeutics Holdings Inc (RANI)
Key Facts
| 1 Day | 1 Week | 1 Month | 3 Months | 6 Months | 1 Year | 5 Years | All Time |
| 4.28 | -2.31 | -17.21 | 16.21 | 13.83 | -11.01 | 0.00 | 1,166.67 |
Last 730 data points are shown. To view all data, Upgrade to PRO plan with only $1
| Trading Data | ||
| Close | 3.90 | |
| Open | 3.84 | |
| High | 4.20 | |
| Low | 3.82 | |
| Volume | 21,821 | |
| Change | 0.16 | |
| Change % | 4.28 | |
| Avg Volume (20 Days) | 53,410 | |
| Volume/Avg Volume (20 Days) Ratio | 0.41 | |
| 52 Week Range | 1.82 - 8.75 | |
| Price vs 52 Week High | -55.43% | |
| Price vs 52 Week Low | 114.29% | |
| Range | -7.54 | |
| Gap Up/Down | -0.26 | |
Fundamentals | ||
| Market Capitalization (Mln) | 189 | |
| EBIDTA | 0 | |
| PE Ratio | 0.0000 | |
| PEG Ratio | 0.0000 | |
| WallStreet Target Price | 28.40 | |
| Book Value | 2.6060 | |
| Earnings Per Share | -1.0070 | |
| EPS Estimate Current Quarter | -0.1800 | |
| EPS Estimate Next Quarter | -0.2200 | |
| EPS Estimate Current Year | -0.7300 | |
| EPS Estimate Next Year | -1.1600 | |
| Diluted EPS (TTM) | -1.0070 | |
| Revenues | ||
| Profit Marging | 0.0000 | |
| Operating Marging (TTM) | -14.7527 | |
| Return on asset (TTM) | 0.0000 | |
| Return on equity (TTM) | 0.0000 | |
| Revenue TTM | 2,927,000 | |
| Revenue per share TTM | 0.1480 | |
| Quarterly Revenue Growth (YOY) | 31.6830 | |
| Quarterly Earnings Growth (YOY) | 0.0000 | |
| Gross Profit (TTM) | 462,000 | |
| Dividends | ||
| Dividend Share | 0.0000 | |
| Dividend Yield | ||
| Valuations | ||
| Trailing PE | 0.0000 | |
| Forward PE | 0.0000 | |
| Price Sales (TTM) | 0.0000 | |
| Price Book (MRQ) | 7.4832 | |
| Revenue Enterprise Value | 108.9688 | |
| EBITDA Enterprise Value | 0.0000 | |
| Shares | ||
| Shares Outstanding | 19,711,900 | |
| Shares Float | 7,029,649 | |
| Shares Short | 0 | |
| Shares Short (Prior Month) | 0 | |
| Shares Ratio | 0.00 | |
| Short Outstanding (%) | 0.00 | |
| Short Float (%) | 0.00 | |
| Insider (%) | 63.19 | |
| Institutions (%) | 3.61 | |
06/24 07:00 EST - globenewswire.com
Rani Therapeutics Announces Partnership with ProGen on Development of Oral Obesity Treatment
~ New RT-114 obesity program combines ProGen's FC Fusion protein conjugated GLP-1/GLP-2 dual agonist, PG-102, with the RaniPill® capsule designed to provide a differentiated oral delivery mechanism with bioavailability comparable to subcutaneous injection ~
Rani Therapeutics Announces Partnership with ProGen on Development of Oral Obesity Treatment
~ New RT-114 obesity program combines ProGen's FC Fusion protein conjugated GLP-1/GLP-2 dual agonist, PG-102, with the RaniPill® capsule designed to provide a differentiated oral delivery mechanism with bioavailability comparable to subcutaneous injection ~
05/14 08:00 EST - globenewswire.com
Rani Therapeutics to Participate in May Investor Conferences
SAN JOSE, Calif., May 14, 2024 (GLOBE NEWSWIRE) -- Rani Therapeutics Holdings, Inc. (“Rani Therapeutics” or “Rani”) (Nasdaq: RANI), a clinical-stage biotherapeutics company focused on the oral delivery of biologics and drugs, today announced that the Company will participate in two upcoming investor conferences in May 2024. These conferences include:
Rani Therapeutics to Participate in May Investor Conferences
SAN JOSE, Calif., May 14, 2024 (GLOBE NEWSWIRE) -- Rani Therapeutics Holdings, Inc. (“Rani Therapeutics” or “Rani”) (Nasdaq: RANI), a clinical-stage biotherapeutics company focused on the oral delivery of biologics and drugs, today announced that the Company will participate in two upcoming investor conferences in May 2024. These conferences include:
05/09 08:00 EST - globenewswire.com
Rani Therapeutics to Present Clinical and Preclinical Data on Oral Delivery of an Ustekinumab Biosimilar via the RaniPill® Capsule at Digestive Disease Week 2024
SAN JOSE, Calif., May 09, 2024 (GLOBE NEWSWIRE) -- Rani Therapeutics Holdings, Inc. (“Rani Therapeutics” or “Rani”) (Nasdaq: RANI), a clinical-stage biotherapeutics company focused on the oral delivery of biologics and drugs, today announced that it will present clinical and preclinical and data on the RaniPill® capsule, the company's oral delivery platform, at Digestive Disease Week® (DDW) taking place both virtually and in-person on May 18-21, 2024 in Washington, DC.
Rani Therapeutics to Present Clinical and Preclinical Data on Oral Delivery of an Ustekinumab Biosimilar via the RaniPill® Capsule at Digestive Disease Week 2024
SAN JOSE, Calif., May 09, 2024 (GLOBE NEWSWIRE) -- Rani Therapeutics Holdings, Inc. (“Rani Therapeutics” or “Rani”) (Nasdaq: RANI), a clinical-stage biotherapeutics company focused on the oral delivery of biologics and drugs, today announced that it will present clinical and preclinical and data on the RaniPill® capsule, the company's oral delivery platform, at Digestive Disease Week® (DDW) taking place both virtually and in-person on May 18-21, 2024 in Washington, DC.
05/06 16:05 EST - globenewswire.com
Rani Therapeutics Reports First Quarter 2024 Financial Results; Provides Corporate Update
- Announced Positive Topline Results from Phase 1 Study of an Oral Anti-Interleukin 12/23 Antibody (RT-111) - - Initiation of Phase 2 clinical trial for RT-102 for the treatment of osteoporosis expected in 2024 - - RaniPill HC to be ready for potential Phase 1 clinical trials in the second half of 2024 - SAN JOSE, Calif., May 06, 2024 (GLOBE NEWSWIRE) -- Rani Therapeutics Holdings, Inc. (“Rani Therapeutics” or “Rani”) (Nasdaq: RANI), a clinical-stage biotherapeutics company focused on the oral delivery of biologics and drugs, today reported financial results for the quarter ended March 31, 2024 and provided a corporate update.
Rani Therapeutics Reports First Quarter 2024 Financial Results; Provides Corporate Update
- Announced Positive Topline Results from Phase 1 Study of an Oral Anti-Interleukin 12/23 Antibody (RT-111) - - Initiation of Phase 2 clinical trial for RT-102 for the treatment of osteoporosis expected in 2024 - - RaniPill HC to be ready for potential Phase 1 clinical trials in the second half of 2024 - SAN JOSE, Calif., May 06, 2024 (GLOBE NEWSWIRE) -- Rani Therapeutics Holdings, Inc. (“Rani Therapeutics” or “Rani”) (Nasdaq: RANI), a clinical-stage biotherapeutics company focused on the oral delivery of biologics and drugs, today reported financial results for the quarter ended March 31, 2024 and provided a corporate update.
03/20 19:05 EST - seekingalpha.com
Rani Therapeutics Holdings, Inc. (RANI) Q4 2023 Earnings Call Transcript
Rani Therapeutics Holdings, Inc. (RANI) Q4 2023 Earnings Call Transcript
Rani Therapeutics Holdings, Inc. (RANI) Q4 2023 Earnings Call Transcript
Rani Therapeutics Holdings, Inc. (RANI) Q4 2023 Earnings Call Transcript
03/20 16:05 EST - globenewswire.com
Rani Therapeutics Reports Fourth Quarter and Full Year 2023 Financial Results; Provides Corporate Update
- Announced Positive Topline Results from Phase 1 Study of an Oral Anti-Interleukin 12/23 Antibody (RT-111) - - Announced Preclinical Pharmacodynamic Data on Transenteric Delivery of GLP-1 Incretin Triagonist - - Cash runway extended into 2025 - - Conference call and webcast today at 4:30 p.m. ET / 1:30 p.m.
Rani Therapeutics Reports Fourth Quarter and Full Year 2023 Financial Results; Provides Corporate Update
- Announced Positive Topline Results from Phase 1 Study of an Oral Anti-Interleukin 12/23 Antibody (RT-111) - - Announced Preclinical Pharmacodynamic Data on Transenteric Delivery of GLP-1 Incretin Triagonist - - Cash runway extended into 2025 - - Conference call and webcast today at 4:30 p.m. ET / 1:30 p.m.
03/15 16:05 EST - globenewswire.com
Rani Therapeutics to Report Fourth Quarter and Full Year 2023 Financial Results
SAN JOSE, Calif., March 15, 2024 (GLOBE NEWSWIRE) -- Rani Therapeutics Holdings, Inc. (“Rani Therapeutics” or “Rani”) (Nasdaq: RANI), a clinical-stage biotherapeutics company focused on the oral delivery of biologics and drugs, today announced that it plans to release financial results for the fourth quarter and full year ended December 31, 2023 and provide a business update on Wednesday, March 20 after the close of trading. Rani's management team will host a conference call and webcast beginning at 4:30 p.m. ET.
Rani Therapeutics to Report Fourth Quarter and Full Year 2023 Financial Results
SAN JOSE, Calif., March 15, 2024 (GLOBE NEWSWIRE) -- Rani Therapeutics Holdings, Inc. (“Rani Therapeutics” or “Rani”) (Nasdaq: RANI), a clinical-stage biotherapeutics company focused on the oral delivery of biologics and drugs, today announced that it plans to release financial results for the fourth quarter and full year ended December 31, 2023 and provide a business update on Wednesday, March 20 after the close of trading. Rani's management team will host a conference call and webcast beginning at 4:30 p.m. ET.
01/09 08:30 EST - prnewswire.com
SHAREHOLDER ALERT: Purcell & Lefkowitz LLP Announces Shareholder Investigation of Rani Therapeutics Holdings, Inc. (NASDAQ: RANI)
NEW YORK , Jan. 9, 2024 /PRNewswire/ -- Purcell & Lefkowitz LLP announces that it is investigating Rani Therapeutics Holdings, Inc. (NASDAQ: RANI) on behalf of the company's shareholders. The investigation seeks to determine whether Rani Therapeutics's directors breached their fiduciary duties in connection with recent corporate actions that have caused a decline in Rani Therapeutics's stock price.
SHAREHOLDER ALERT: Purcell & Lefkowitz LLP Announces Shareholder Investigation of Rani Therapeutics Holdings, Inc. (NASDAQ: RANI)
NEW YORK , Jan. 9, 2024 /PRNewswire/ -- Purcell & Lefkowitz LLP announces that it is investigating Rani Therapeutics Holdings, Inc. (NASDAQ: RANI) on behalf of the company's shareholders. The investigation seeks to determine whether Rani Therapeutics's directors breached their fiduciary duties in connection with recent corporate actions that have caused a decline in Rani Therapeutics's stock price.
12/14 08:00 EST - globenewswire.com
Rani Therapeutics Announces Preclinical Pharmacodynamic Data on Transenteric Delivery of GLP-1 Incretin Triagonist
- Transenteric delivery of incretin triagonist of GLP-1, GIP, glucagon receptors elicits rapid weight loss in animal study –
Rani Therapeutics Announces Preclinical Pharmacodynamic Data on Transenteric Delivery of GLP-1 Incretin Triagonist
- Transenteric delivery of incretin triagonist of GLP-1, GIP, glucagon receptors elicits rapid weight loss in animal study –
12/07 13:32 EST - zacks.com
What Makes Rani Therapeutics Holdings, Inc. (RANI) a New Buy Stock
Rani Therapeutics Holdings, Inc. (RANI) might move higher on growing optimism about its earnings prospects, which is reflected by its upgrade to a Zacks Rank #2 (Buy).
What Makes Rani Therapeutics Holdings, Inc. (RANI) a New Buy Stock
Rani Therapeutics Holdings, Inc. (RANI) might move higher on growing optimism about its earnings prospects, which is reflected by its upgrade to a Zacks Rank #2 (Buy).
11/08 16:05 EST - globenewswire.com
Rani Therapeutics Reports Third Quarter 2023 Financial Results; Provides Corporate Update
- Cash runway extended into 2025 - - Announced strategic program prioritization, expansion of manufacturing and plans to streamline business operations - - Initiated Phase 1 clinical trial of RT-111, a RaniPill GO containing ustekinumab biosimilar CT-P43, with topline results expected in 1Q 2024 - - Initiation of Phase 2 clinical trial of RT-102, a RaniPill GO containing teriparatide for osteoporosis, expected by the year-end 2023 - - Announced RaniPill capsule was well-tolerated in 60-day, repeat oral-administration GLP safety study - - Announced successful drug delivery with RaniPill HC high-capacity capsule in multiple preclinical studies with cumulative >90% success rate - SAN JOSE, Calif., Nov. 08, 2023 (GLOBE NEWSWIRE) -- Rani Therapeutics Holdings, Inc. (“Rani Therapeutics” or “Rani”) (Nasdaq: RANI), a clinical-stage biotherapeutics company focused on the oral delivery of biologics and drugs, today reported financial results for the third quarter ended September 30, 2023, and provided a corporate update.
Rani Therapeutics Reports Third Quarter 2023 Financial Results; Provides Corporate Update
- Cash runway extended into 2025 - - Announced strategic program prioritization, expansion of manufacturing and plans to streamline business operations - - Initiated Phase 1 clinical trial of RT-111, a RaniPill GO containing ustekinumab biosimilar CT-P43, with topline results expected in 1Q 2024 - - Initiation of Phase 2 clinical trial of RT-102, a RaniPill GO containing teriparatide for osteoporosis, expected by the year-end 2023 - - Announced RaniPill capsule was well-tolerated in 60-day, repeat oral-administration GLP safety study - - Announced successful drug delivery with RaniPill HC high-capacity capsule in multiple preclinical studies with cumulative >90% success rate - SAN JOSE, Calif., Nov. 08, 2023 (GLOBE NEWSWIRE) -- Rani Therapeutics Holdings, Inc. (“Rani Therapeutics” or “Rani”) (Nasdaq: RANI), a clinical-stage biotherapeutics company focused on the oral delivery of biologics and drugs, today reported financial results for the third quarter ended September 30, 2023, and provided a corporate update.
10/19 16:05 EST - globenewswire.com
Rani Therapeutics Announces Successful Oral Delivery of Monoclonal Antibody via High-Capacity Pill in Preclinical Study
- RaniPill ® HC achieved 4/4 successful drug delivery of orally administered Humira® (adalimumab) -
Rani Therapeutics Announces Successful Oral Delivery of Monoclonal Antibody via High-Capacity Pill in Preclinical Study
- RaniPill ® HC achieved 4/4 successful drug delivery of orally administered Humira® (adalimumab) -
10/12 16:05 EST - globenewswire.com
Rani Therapeutics to Present Abstract on RT-102 at the 2023 Annual Meeting of the American Society for Bone and Mineral Research
SAN JOSE, Calif., Oct. 12, 2023 (GLOBE NEWSWIRE) -- Rani Therapeutics Holdings, Inc. (“Rani Therapeutics” or “Rani”) (Nasdaq: RANI), a clinical-stage biotherapeutics company focused on the oral delivery of biologics and drugs, today announced that it will present an abstract on RT-102 at the 2023 Annual Meeting of the American Society for Bone and Mineral Research (ASBMR) taking place on October 13-16, 2023 in Vancouver, British Columbia, Canada.
Rani Therapeutics to Present Abstract on RT-102 at the 2023 Annual Meeting of the American Society for Bone and Mineral Research
SAN JOSE, Calif., Oct. 12, 2023 (GLOBE NEWSWIRE) -- Rani Therapeutics Holdings, Inc. (“Rani Therapeutics” or “Rani”) (Nasdaq: RANI), a clinical-stage biotherapeutics company focused on the oral delivery of biologics and drugs, today announced that it will present an abstract on RT-102 at the 2023 Annual Meeting of the American Society for Bone and Mineral Research (ASBMR) taking place on October 13-16, 2023 in Vancouver, British Columbia, Canada.
09/18 08:00 EST - globenewswire.com
Rani Therapeutics Initiates Phase 1 Study of RT-111 (RaniPill® Containing Ustekinumab Biosimilar, CT-P43)
- Topline results from this study are expected in early Q1 2024 - Celltrion has a right of first negotiation for RT-111 following positive Phase 1 results SAN JOSE, Calif., Sept. 18, 2023 (GLOBE NEWSWIRE) -- Rani Therapeutics Holdings, Inc. (“Rani Therapeutics” or “Rani”) (Nasdaq: RANI), a clinical-stage biotherapeutics company focused on the oral delivery of biologics and drugs, today announced the initiation of a Phase 1 clinical trial to evaluate the safety and tolerability of RT-111, an orally administered RaniPill®GO capsule containing an ustekinumab biosimilar, CT-P43.
Rani Therapeutics Initiates Phase 1 Study of RT-111 (RaniPill® Containing Ustekinumab Biosimilar, CT-P43)
- Topline results from this study are expected in early Q1 2024 - Celltrion has a right of first negotiation for RT-111 following positive Phase 1 results SAN JOSE, Calif., Sept. 18, 2023 (GLOBE NEWSWIRE) -- Rani Therapeutics Holdings, Inc. (“Rani Therapeutics” or “Rani”) (Nasdaq: RANI), a clinical-stage biotherapeutics company focused on the oral delivery of biologics and drugs, today announced the initiation of a Phase 1 clinical trial to evaluate the safety and tolerability of RT-111, an orally administered RaniPill®GO capsule containing an ustekinumab biosimilar, CT-P43.
09/07 16:05 EST - globenewswire.com
Rani Therapeutics Announces Successful Drug Delivery of High-Capacity Pill in Preclinical Studies
- Two preclinical studies of RaniPill® HC achieved 18/20 successful drug delivery of orally administered teriparatide resulting in a cumulative 90% success rate
Rani Therapeutics Announces Successful Drug Delivery of High-Capacity Pill in Preclinical Studies
- Two preclinical studies of RaniPill® HC achieved 18/20 successful drug delivery of orally administered teriparatide resulting in a cumulative 90% success rate
09/06 08:00 EST - globenewswire.com
Rani Therapeutics to Participate in September Investor Conferences
SAN JOSE, Calif., Sept. 06, 2023 (GLOBE NEWSWIRE) -- Rani Therapeutics Holdings, Inc. (“Rani Therapeutics” or “Rani”) (Nasdaq: RANI), a clinical-stage biotherapeutics company focused on the oral delivery of biologics and drugs, today announced that Rani will participate in and present at two upcoming investor conferences in September 2023. These conferences include:
Rani Therapeutics to Participate in September Investor Conferences
SAN JOSE, Calif., Sept. 06, 2023 (GLOBE NEWSWIRE) -- Rani Therapeutics Holdings, Inc. (“Rani Therapeutics” or “Rani”) (Nasdaq: RANI), a clinical-stage biotherapeutics company focused on the oral delivery of biologics and drugs, today announced that Rani will participate in and present at two upcoming investor conferences in September 2023. These conferences include:
08/11 16:05 EST - globenewswire.com
Rani Therapeutics Reports Second Quarter 2023 Financial Results; Provides Corporate Update
- Expansion of partnership with Celltrion for development of RT-105 to complement existing partnership for RT-111 - Appointment of Kate McKinley as Chief Business Officer - Presentation of three abstracts on RT-102 and RT-112 at the Endocrine Society Annual Conference and selection as winner of Presidential Poster Competition in its category for exceptional scientific work on RT-102 - Presentation of late-breaking abstract on oral delivery of GLP-1 agonist at American Diabetes Association's Scientific Sessions - Plan to initiate Phase 2 study for RT-102 and Phase 1 study for RT-111 in 2H of 2023 SAN JOSE, Calif., Aug. 11, 2023 (GLOBE NEWSWIRE) -- Rani Therapeutics Holdings, Inc. (“Rani Therapeutics” or “Rani”) (Nasdaq: RANI), a clinical-stage biotherapeutics company focused on the oral delivery of biologics and drugs, today reported financial results for the quarter ended June 30, 2023, and provided a corporate update.
Rani Therapeutics Reports Second Quarter 2023 Financial Results; Provides Corporate Update
- Expansion of partnership with Celltrion for development of RT-105 to complement existing partnership for RT-111 - Appointment of Kate McKinley as Chief Business Officer - Presentation of three abstracts on RT-102 and RT-112 at the Endocrine Society Annual Conference and selection as winner of Presidential Poster Competition in its category for exceptional scientific work on RT-102 - Presentation of late-breaking abstract on oral delivery of GLP-1 agonist at American Diabetes Association's Scientific Sessions - Plan to initiate Phase 2 study for RT-102 and Phase 1 study for RT-111 in 2H of 2023 SAN JOSE, Calif., Aug. 11, 2023 (GLOBE NEWSWIRE) -- Rani Therapeutics Holdings, Inc. (“Rani Therapeutics” or “Rani”) (Nasdaq: RANI), a clinical-stage biotherapeutics company focused on the oral delivery of biologics and drugs, today reported financial results for the quarter ended June 30, 2023, and provided a corporate update.
08/04 16:05 EST - globenewswire.com
Rani Therapeutics to Participate in August Investor Conferences
SAN JOSE, Calif., Aug. 04, 2023 (GLOBE NEWSWIRE) -- Rani Therapeutics Holdings, Inc. (“Rani Therapeutics” or “Rani”) (Nasdaq: RANI), a clinical-stage biotherapeutics company focused on the oral delivery of biologics and drugs, today announced that the Company will participate in three upcoming investor conferences in August 2023. These conferences include:
Rani Therapeutics to Participate in August Investor Conferences
SAN JOSE, Calif., Aug. 04, 2023 (GLOBE NEWSWIRE) -- Rani Therapeutics Holdings, Inc. (“Rani Therapeutics” or “Rani”) (Nasdaq: RANI), a clinical-stage biotherapeutics company focused on the oral delivery of biologics and drugs, today announced that the Company will participate in three upcoming investor conferences in August 2023. These conferences include:
05/05 17:33 EST - seekingalpha.com
Rani Therapeutics: Novel Drug Delivery System, Under-Covered And Early Stage
Rani Therapeutics Holdings, Inc. has an exciting oral drug delivery system for biologics. It has shown excellent early data in trials.
Rani Therapeutics: Novel Drug Delivery System, Under-Covered And Early Stage
Rani Therapeutics Holdings, Inc. has an exciting oral drug delivery system for biologics. It has shown excellent early data in trials.
05/02 12:30 EST - businesswire.com
Pluto Biosciences Raises $3.7M to Revolutionize Biological Data Interpretation and Accelerate Life Sciences Discoveries
DENVER--(BUSINESS WIRE)--Pluto Biosciences, a cutting-edge life sciences software-as-a-service (SaaS) platform, announced today the closing of a $3.7 million seed round led by Silverton Partners in Austin, TX. This investment will fuel the expansion of Pluto's innovative platform, which gives scientific teams both a unified home for managing their biological data, and an industry-first, interactive canvas for analyzing and visualizing complex biological data sets using no-code computational biology pipelines. Since its launch in 2021 from the Wyss Institute at Harvard University, Pluto has become a trusted partner for life sciences organizations in the US and UK, ranging in size and domain from academia to public biopharma. With its biology-focused user experience, Pluto offers flexibility and ease-of-use when running bioinformatics analyses and creating plots, allowing researchers to focus on making groundbreaking discoveries and presenting them for maximum impact. "Pluto is breaking down the obstacles that have traditionally prevented the widespread use of computational biology, including the need for compute infrastructure and black box ‘pipelines’, and empowering scientists to play an active role in their scientific discoveries,” says Rani Powers, PhD, CEO and Founder of Pluto. Dr. Powers is confident that the investment will accelerate Pluto's growth and enable the Company to reach even more organizations in the life sciences industry. “With Silverton Partners' support, we will be able to increase sales velocity with the ultimate goal of transforming the way life sciences research is conducted.” Mike Dodd, General Partner at Silverton Partners, brings extensive experience in technology investing and a strong track record of success. Silverton Partners is known for investing in early-stage ventures tackling growth markets and building lasting companies, and their support of Pluto underscores their confidence in the Company's potential for long-term growth. "We were impressed by Pluto’s innovative product and ability to solve real needs currently slowing the pace of discovery in the life sciences industry," says Dodd. "The platform's seamless integration of data management, computational biology algorithms, and visualization capabilities sets it apart from competitors, and we believe the Company is poised for significant growth in the coming years." Scientists currently use Pluto to accelerate biological applications spanning from preclinical and translational science research, to cell and gene therapies, drug discovery and development, and clinical research. Built to be flexible for the wide range of experiments a scientific team can perform, the platform can be used to analyze data from popular next-generation sequencing-based assays such as RNA-seq, ChIP-seq, CUT&RUN, and CRISPR screens, as well as data from other workhorse assays for pharma and biotech including metabolomics, proteomics, biochemical assays, and animal behavioral studies. The Pluto platform also integrates with sequencing services, electronic lab notebooks, project management platforms, and other collaboration tools. Pluto will use the funding to further build out the product and go-to-market teams, and develop advanced product features. About Pluto Headquartered in Denver, CO, Pluto is re-envisioning the scientific research process from the ground up. Built for life science organizations of all sizes, Pluto delivers a visually elegant platform that allows for easy management of lab projects, secure data sharing with collaborators, as well as execution of computational biology analyses and visualization. For more information, visit https://pluto.bio. About Silverton Partners Silverton Partners is Texas’ most active and longest standing venture capital investor. With a focus on long-term partnerships, Silverton invests in innovative technology companies led by founders who share in our commitment to disrupt growth markets and build enduring companies. For more information, visit https://www.silvertonpartners.com.
Pluto Biosciences Raises $3.7M to Revolutionize Biological Data Interpretation and Accelerate Life Sciences Discoveries
DENVER--(BUSINESS WIRE)--Pluto Biosciences, a cutting-edge life sciences software-as-a-service (SaaS) platform, announced today the closing of a $3.7 million seed round led by Silverton Partners in Austin, TX. This investment will fuel the expansion of Pluto's innovative platform, which gives scientific teams both a unified home for managing their biological data, and an industry-first, interactive canvas for analyzing and visualizing complex biological data sets using no-code computational biology pipelines. Since its launch in 2021 from the Wyss Institute at Harvard University, Pluto has become a trusted partner for life sciences organizations in the US and UK, ranging in size and domain from academia to public biopharma. With its biology-focused user experience, Pluto offers flexibility and ease-of-use when running bioinformatics analyses and creating plots, allowing researchers to focus on making groundbreaking discoveries and presenting them for maximum impact. "Pluto is breaking down the obstacles that have traditionally prevented the widespread use of computational biology, including the need for compute infrastructure and black box ‘pipelines’, and empowering scientists to play an active role in their scientific discoveries,” says Rani Powers, PhD, CEO and Founder of Pluto. Dr. Powers is confident that the investment will accelerate Pluto's growth and enable the Company to reach even more organizations in the life sciences industry. “With Silverton Partners' support, we will be able to increase sales velocity with the ultimate goal of transforming the way life sciences research is conducted.” Mike Dodd, General Partner at Silverton Partners, brings extensive experience in technology investing and a strong track record of success. Silverton Partners is known for investing in early-stage ventures tackling growth markets and building lasting companies, and their support of Pluto underscores their confidence in the Company's potential for long-term growth. "We were impressed by Pluto’s innovative product and ability to solve real needs currently slowing the pace of discovery in the life sciences industry," says Dodd. "The platform's seamless integration of data management, computational biology algorithms, and visualization capabilities sets it apart from competitors, and we believe the Company is poised for significant growth in the coming years." Scientists currently use Pluto to accelerate biological applications spanning from preclinical and translational science research, to cell and gene therapies, drug discovery and development, and clinical research. Built to be flexible for the wide range of experiments a scientific team can perform, the platform can be used to analyze data from popular next-generation sequencing-based assays such as RNA-seq, ChIP-seq, CUT&RUN, and CRISPR screens, as well as data from other workhorse assays for pharma and biotech including metabolomics, proteomics, biochemical assays, and animal behavioral studies. The Pluto platform also integrates with sequencing services, electronic lab notebooks, project management platforms, and other collaboration tools. Pluto will use the funding to further build out the product and go-to-market teams, and develop advanced product features. About Pluto Headquartered in Denver, CO, Pluto is re-envisioning the scientific research process from the ground up. Built for life science organizations of all sizes, Pluto delivers a visually elegant platform that allows for easy management of lab projects, secure data sharing with collaborators, as well as execution of computational biology analyses and visualization. For more information, visit https://pluto.bio. About Silverton Partners Silverton Partners is Texas’ most active and longest standing venture capital investor. With a focus on long-term partnerships, Silverton invests in innovative technology companies led by founders who share in our commitment to disrupt growth markets and build enduring companies. For more information, visit https://www.silvertonpartners.com.